The impact of population ageing on the burden of chronic kidney disease
The burden of chronic kidney disease (CKD) and its risk factors are projected to rise in
parallel with the rapidly ageing global population. By 2050, the prevalence of CKD category …
parallel with the rapidly ageing global population. By 2050, the prevalence of CKD category …
Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes
M Vaduganathan, G Filippatos, BL Claggett… - Nature medicine, 2024 - nature.com
Cardiovascular-kidney-metabolic syndrome is an emerging entity that connects
cardiovascular diseases, chronic kidney disease and diabetes. The non-steroidal …
cardiovascular diseases, chronic kidney disease and diabetes. The non-steroidal …
Cardiovascular and non‐renal complications of chronic kidney disease: Managing risk
Chronic kidney disease (CKD) currently affects approximately 850 million people globally
and is continuing to increase in prevalence as well as in importance as a cause of death …
and is continuing to increase in prevalence as well as in importance as a cause of death …
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial
J Deanfield, S Verma, BM Scirica, SE Kahn… - The Lancet, 2024 - thelancet.com
Background Semaglutide, a GLP-1 receptor agonist, reduces the risk of major adverse
cardiovascular events (MACE) in people with overweight or obesity, but the effects of this …
cardiovascular events (MACE) in people with overweight or obesity, but the effects of this …
Glycaemic control is still central in the hierarchy of priorities in type 2 diabetes management
K Khunti, F Zaccardi, A Amod, VR Aroda, P Aschner… - Diabetologia, 2024 - Springer
A panel of primary care and diabetes specialists conducted focused literature searches on
the current role of glycaemic control in the management of type 2 diabetes and revisited the …
the current role of glycaemic control in the management of type 2 diabetes and revisited the …
Chronic kidney disease in type 2 diabetes: the size of the problem, addressing residual renal risk and what we have learned from the CREDENCE trial
K Chaudhry, J Karalliedde - Diabetes, Obesity and Metabolism, 2024 - Wiley Online Library
Chronic kidney disease (CKD) associated with type 2 diabetes (T2DM) is a global
challenge; progression to end‐stage kidney disease (ESKD) and increased risk of …
challenge; progression to end‐stage kidney disease (ESKD) and increased risk of …
Efficacy of probiotics/synbiotics supplementation in patients with chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials
C Liu, L Yang, W Wei, P Fu - Frontiers in Nutrition, 2024 - frontiersin.org
Background Chronic kidney disease (CKD) is a serious and steadily growing health problem
worldwide. Probiotic and synbiotic supplementation are expected to improve kidney function …
worldwide. Probiotic and synbiotic supplementation are expected to improve kidney function …
GLP-1 receptor agonists and SGLT2 inhibitors in type 2 diabetes: pleiotropic cardiometabolic effects and add-on value of a combined therapy
AJ Scheen - Drugs, 2024 - Springer
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2
inhibitors (SGLT2is) have proven efficacy and safety in randomized clinical trials and …
inhibitors (SGLT2is) have proven efficacy and safety in randomized clinical trials and …
Reframing “chronicity” with “urgency” in chronic kidney disease management
Clinical Journal of the American Society of Nephrology Page 1 Clinical Journal of the American
Society of Nephrology Reframing “Chronicity” with “Urgency” in Chronic Kidney Disease …
Society of Nephrology Reframing “Chronicity” with “Urgency” in Chronic Kidney Disease …
Clinical trial designs of emerging therapies for diabetic kidney disease (DKD)
AK Singh, YMK Farag, Z Zheng… - Postgraduate Medicine, 2024 - Taylor & Francis
Current evidence for medical therapies for diabetic kidney disease (DKD) is largely based
on large-scale clinical trials. These trials, however, often exhibit heterogeneity in participant …
on large-scale clinical trials. These trials, however, often exhibit heterogeneity in participant …